<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1514">
  <stage>Registered</stage>
  <submitdate>29/03/2007</submitdate>
  <approvaldate>29/03/2007</approvaldate>
  <nctid>NCT00455000</nctid>
  <trial_identification>
    <studytitle>A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease</studytitle>
    <scientifictitle>A Phase I, Randomized, Placebo Controlled, Double Blind Dose Escalation Study Of The Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A9951001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - PF-04360365
Treatment: drugs - Placebo

Experimental: Active treatment - 5 possible active doses

Placebo Comparator: Placebo - 


Other interventions: PF-04360365
Monoclonal antibody

Treatment: drugs: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To examine the safety, tolerability, and pharmacokinetics of a single dose of PF-04360365 in subjects with mild to moderate AD for one year following dosing.</outcome>
      <timepoint>366 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To characterize the pharmacokinetic, pharmacodynamic and immunogenicity profile of PF-04360365 for one year following dosing.</outcome>
      <timepoint>366 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or Females of non-childbearing potential, age 50-85

          -  Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1)
             National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's
             Disease and Related Disorders Association (NINCDS-ADRDA); and 2)Diagnostic and
             Statistical Manual of Mental Disorders (DSM IV)

          -  Mini-mental status exam score of 16-26 inclusive

          -  Rosen-Modified Hachinski Ischemia Score &lt; or = 4</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis or history of other dementia or neurodegenerative disorders

          -  Diagnosis or history of clinically significant cerebrovascular disease

          -  Specific findings on magnetic resonance imaging (MRI): cortical infarct, micro
             hemorrhage, multiple white matter lacunes, extensive white matter abnormalities

          -  History of autoimmune disorders

          -  History of allergic or anaphylactic reactions</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>37</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Heidelberg West</hospital>
    <hospital>Pfizer Investigational Site - Fremantle</hospital>
    <hospital>Pfizer Investigational Site - Nedlands</hospital>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is determine whether a single IV dose of PF-04360365 is safe and
      well tolerated in Adults with Mild to Moderate Alzheimer's disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00455000</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>